TAIGEN BIOTECHNOLOGY CO.,LTD

Company Type: Factory (Manufacturer)

Company Introduction:

TAIGEN BIOTECHNOLOGY CO.,LTD is a prominent biopharmaceutical company based in Taiwan, primarily focused on the research, development, manufacturing, and commercialization of novel therapeutic drugs.

The company's core mission is to address significant unmet medical needs, with a particular emphasis on therapeutic areas such as infectious diseases (especially those caused by multi-drug resistant bacteria), oncology (cancer), and diabetes. Taigen Biotechnology has a strong track record in drug discovery and development, with its pipeline including several proprietary drug candidates. One of its most notable achievements is Nemonoxacin (marketed as Taigexyn), a novel non-fluorinated quinolone antibiotic available in both oral and intravenous formulations, which has received marketing approvals in various territories.

As an integrated biopharmaceutical entity, Taigen Biotechnology not only conducts extensive research and development but also manages or oversees the manufacturing processes for its proprietary drug products. This comprehensive operational structure, from discovery to production and commercialization, firmly establishes it as a manufacturer rather than solely a trading company.

TAIGEN BIOTECHNOLOGY CO.,LTD from Taiwan manufactures or sells the following products:

Nemonoxacin (TG-2550): A novel broad-spectrum non-fluorinated quinolone antibiotic.

Burixafor (TG-0054): A small molecule CXCR4 antagonist for hematopoietic stem cell mobilization.

TG-1000: A novel non-opioid analgesic.